Evelo Biosciences - oral biologics producing systemic therapeutic results


Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, with systemic therapeutic effects. This plays a central role in governing the immune, metabolic, and neurological systems. Evelo's therapies have the potential to improve the lives of people with inflammatory diseases, including COVID-19, and cancer. Evelo Biosciences and Abdul Latif Jameel Health announced a strategic collaboration in early 2021 to develop and commercialize novel therapy EDP1815 for inflammatory diseases and COVID-19, across select developing markets serving over 1.7 billion people. Contact us: info@aljhealth.com Learn more about our collaboration here: https://www.youtube.com/watch?v=_gLe9rSk0T0

Log in